"Factive" inducing foreign capital investment.

Published: 2003-04-16 07:00:00

Updated: 2003-04-16 07:00:00

For the first time in Korea "Factive", a novel antibiotic agent originally developed by LGCI, has been approved by the U. S. FDA, indicating its high technology of Korea for the new drug manufacture and the sustained technology innovation in Korea, which eventually may contribute to more foreigne...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK